Reflecting on the learning during the pandemic, industry is aiming to push innovation in R&D and implement automation and digital technologies across various operational levels.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The jump in profit is due to the better performance of the API business.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
The partnership is a significant step in delivering advanced cancer therapies to patients.
This partnership is in line with the strategic focus of DKSH Business Unit Technology to solidify its position as a leading integrated solutions provider for the scientific Instrumentation market
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business
The commercial production in the SML was started in November 1989.
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Subscribe To Our Newsletter & Stay Updated
